LADENBURG THALM/SH SH Upgrades Compass Therapeutics (NASDAQ:CMPX) to “Buy”

LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics (NASDAQ:CMPX) from a neutral rating to a buy rating in a research note published on Monday morning, MarketBeat reports. LADENBURG THALM/SH SH currently has $5.00 price objective on the stock.

Several other brokerages have also recently issued reports on CMPX. Wedbush reaffirmed an outperform rating and set a $8.00 price objective on shares of Compass Therapeutics in a report on Wednesday, August 7th. HC Wainwright reaffirmed a buy rating and set a $10.00 price target on shares of Compass Therapeutics in a research note on Monday, August 12th.

Compass Therapeutics Stock Performance

Shares of NASDAQ:CMPX opened at $1.73 on Monday. The firm has a market cap of $238.03 million, a price-to-earnings ratio of -4.81 and a beta of 0.88. The firm has a fifty day moving average price of $1.23 and a 200 day moving average price of $1.43. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.34.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.10) EPS for the quarter, meeting the consensus estimate of ($0.10). The company had revenue of $0.85 million for the quarter. As a group, research analysts predict that Compass Therapeutics will post -0.42 earnings per share for the current year.

Hedge Funds Weigh In On Compass Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Bleakley Financial Group LLC purchased a new position in Compass Therapeutics during the first quarter worth $80,000. Element Capital Management LLC bought a new position in Compass Therapeutics during the 4th quarter valued at about $458,000. Pale Fire Capital SE raised its position in Compass Therapeutics by 301.0% in the 4th quarter. Pale Fire Capital SE now owns 181,055 shares of the company’s stock worth $282,000 after purchasing an additional 135,900 shares during the period. Vanguard Group Inc. lifted its stake in Compass Therapeutics by 1.7% in the first quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock worth $8,221,000 after purchasing an additional 71,008 shares during the last quarter. Finally, Pennant Investors LP purchased a new position in shares of Compass Therapeutics during the fourth quarter valued at approximately $310,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.